An open‐label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid‐dependent/steroid‐resistant chronic GVHD

Authors:

Published: 0000-00-00

DOI: HTTPS://DOI.ORG/10.1002/ajh.27424

Keywords:

Abstract:

Source: